Xilio Therapeutics Launches Phase 2 Trial for Efarindodekin Alfa (XTX301), a Tumor-Activated IL-12, and Reaches $17.5 Million Development Milestone in Exclusive Partnership with Gilead
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 09 2025
0mins
Should l Buy XLO?
Source: Newsfilter
Efarindodekin Alfa Clinical Trial: Xilio Therapeutics has initiated patient dosing in Phase 2 of a clinical trial for efarindodekin alfa (XTX301), a tumor-activated IL-12, after demonstrating promising anti-tumor activity and a well-tolerated safety profile in Phase 1.
Financial Milestone Achievement: The company achieved a $17.5 million development milestone under its license agreement with Gilead Sciences, extending its cash runway into the first quarter of 2027, with current cash and equivalents reported at $121.6 million.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy XLO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on XLO
About XLO
Xilio Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. It is using its proprietary platform to build a pipeline of novel, tumor-activated I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines, antibodies, bispecific and immune cell engagers. Its pipeline products include Vilastobart (XTX101), XTX301, XTX501, and tumor-activated bispecific molecules and immune cell-engaging molecules. XTX101 is an investigational tumor-activated, Fc-enhanced, high-affinity binding anti-CTLA-4 monoclonal antibody. XTX301, a tumor-activated, engineered interleukin 12, or IL-12, therapy.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
XILIO THERAPEUTICS INC Reports Q4 Net Income of $10.36 Million
Company Overview: The article discusses the financial performance of a company named X, specifically focusing on its net income for the fourth quarter.
Financial Results: X reported a net income of USD 10.36 million for Q4, indicating a significant financial achievement for the period.
See More
XILIO THERAPEUTICS INC - FUNDING NOW SECURED UNTIL THE END OF 2027
Therapeutics in Cash Runway: The company has extended its cash runway through the end of 2027, indicating financial stability for ongoing projects.
Future Plans: This extension allows for continued investment in therapeutic development and potential new initiatives without immediate financial pressure.
See More
Xilio Therapeutics Announces 1-for-14 Reverse Stock Split
- Reverse Stock Split Plan: Xilio Therapeutics announced a 1-for-14 reverse stock split effective March 13, 2026, aimed at increasing the per-share market price to meet Nasdaq's minimum bid price requirement, thereby ensuring continued listing compliance.
- Capital Adjustment Impact: The reverse split will reduce the number of outstanding shares from approximately 73.5 million to about 5.2 million, with trading expected to commence on a split-adjusted basis on March 16, 2026, enhancing per-share value to attract investors.
- Market Reaction: Following the reverse split announcement, XLO shares fell 16.48% in premarket trading to $0.451, indicating market concerns regarding the company's current stock price and future outlook, which may affect investor confidence.
- Compliance Objective: By implementing the reverse stock split, Xilio aims to restore compliance with Nasdaq, ensuring the company can continue trading in the public market and avoid delisting risks due to low stock prices.
See More
Xilio Therapeutics Grants Stock Options to New Employees
- Stock Option Grant: On March 1, 2026, Xilio Therapeutics granted 50,050 non-qualified stock options to two new employees, with an exercise price of $0.5283 per share, reflecting the company's proactive approach to talent acquisition.
- Option Structure: Each stock option has a ten-year term, with 25% of shares vesting after the first year and the remaining 75% vesting in 36 equal monthly installments, designed to incentivize long-term employee retention and enhance company stability.
- Incentive Plan Context: The stock options are granted under Xilio Therapeutics' 2022 Inducement Stock Incentive Plan, aligning with Nasdaq Listing Rule 5635(c)(4) to attract new talent, demonstrating the company's commitment to human resources.
- Strategic Company Goals: Xilio Therapeutics focuses on developing tumor-activated immuno-oncology therapies aimed at improving outcomes for cancer patients, leveraging proprietary technology to advance novel therapeutic molecules, showcasing its innovative capabilities in the biotechnology sector.
See More
Xilio Therapeutics Launches Pre-Funded Warrant Offering
- Offering Size: Xilio Therapeutics is pricing an underwritten offering of approximately 74.8 million pre-funded warrants at $0.5349 each, aiming for gross proceeds of around $40 million, which underscores the company's ability to raise capital in the market.
- Use of Proceeds: The net proceeds from this offering will be allocated towards advancing the development of its product candidates, working capital needs, and other general corporate purposes, indicating the company's commitment to future R&D and market opportunities.
- Transaction Timeline: The offering is expected to close on or about February 13, 2026, reflecting the company's strategic planning in capital operations to ensure funding for future growth.
- Market Reaction: Xilio Therapeutics' financing initiative may impact its stock performance, prompting investors to monitor subsequent market dynamics and the company's progress in product development.
See More
Xilio Therapeutics Prices Pre-Funded Warrant Offering
- Offering Size: Xilio Therapeutics announced the pricing of pre-funded warrants at $0.5349 each for 74,780,300 shares, with expected gross proceeds of approximately $40 million, indicating strong market interest in the company's offerings.
- Use of Proceeds: The net proceeds from this offering will be utilized to advance the development of product candidates and for working capital needs, highlighting the company's commitment to future R&D and market opportunities.
- Investor Participation: The financing was led by existing investor Coastlands Capital and included participation from institutional investors like Gilead Sciences, reflecting strong market confidence and support for Xilio's strategic direction.
- Underwriting Arrangement: Leerink Partners is acting as the sole bookrunner for the offering, ensuring professionalism and efficiency in the financing process, which also lays a solid foundation for future capital operations.
See More
XILIO THERAPEUTICS INC Reports Q4 Net Income of $10.36 Million
Company Overview: The article discusses the financial performance of a company named X, specifically focusing on its net income for the fourth quarter.
Financial Results: X reported a net income of USD 10.36 million for Q4, indicating a significant financial achievement for the period.
See More
XILIO THERAPEUTICS INC - FUNDING NOW SECURED UNTIL THE END OF 2027
Therapeutics in Cash Runway: The company has extended its cash runway through the end of 2027, indicating financial stability for ongoing projects.
Future Plans: This extension allows for continued investment in therapeutic development and potential new initiatives without immediate financial pressure.
See More
Xilio Therapeutics Announces 1-for-14 Reverse Stock Split
- Reverse Stock Split Plan: Xilio Therapeutics announced a 1-for-14 reverse stock split effective March 13, 2026, aimed at increasing the per-share market price to meet Nasdaq's minimum bid price requirement, thereby ensuring continued listing compliance.
- Capital Adjustment Impact: The reverse split will reduce the number of outstanding shares from approximately 73.5 million to about 5.2 million, with trading expected to commence on a split-adjusted basis on March 16, 2026, enhancing per-share value to attract investors.
- Market Reaction: Following the reverse split announcement, XLO shares fell 16.48% in premarket trading to $0.451, indicating market concerns regarding the company's current stock price and future outlook, which may affect investor confidence.
- Compliance Objective: By implementing the reverse stock split, Xilio aims to restore compliance with Nasdaq, ensuring the company can continue trading in the public market and avoid delisting risks due to low stock prices.
See More
Xilio Therapeutics Grants Stock Options to New Employees
- Stock Option Grant: On March 1, 2026, Xilio Therapeutics granted 50,050 non-qualified stock options to two new employees, with an exercise price of $0.5283 per share, reflecting the company's proactive approach to talent acquisition.
- Option Structure: Each stock option has a ten-year term, with 25% of shares vesting after the first year and the remaining 75% vesting in 36 equal monthly installments, designed to incentivize long-term employee retention and enhance company stability.
- Incentive Plan Context: The stock options are granted under Xilio Therapeutics' 2022 Inducement Stock Incentive Plan, aligning with Nasdaq Listing Rule 5635(c)(4) to attract new talent, demonstrating the company's commitment to human resources.
- Strategic Company Goals: Xilio Therapeutics focuses on developing tumor-activated immuno-oncology therapies aimed at improving outcomes for cancer patients, leveraging proprietary technology to advance novel therapeutic molecules, showcasing its innovative capabilities in the biotechnology sector.
See More
Xilio Therapeutics Launches Pre-Funded Warrant Offering
- Offering Size: Xilio Therapeutics is pricing an underwritten offering of approximately 74.8 million pre-funded warrants at $0.5349 each, aiming for gross proceeds of around $40 million, which underscores the company's ability to raise capital in the market.
- Use of Proceeds: The net proceeds from this offering will be allocated towards advancing the development of its product candidates, working capital needs, and other general corporate purposes, indicating the company's commitment to future R&D and market opportunities.
- Transaction Timeline: The offering is expected to close on or about February 13, 2026, reflecting the company's strategic planning in capital operations to ensure funding for future growth.
- Market Reaction: Xilio Therapeutics' financing initiative may impact its stock performance, prompting investors to monitor subsequent market dynamics and the company's progress in product development.
See More
Xilio Therapeutics Prices Pre-Funded Warrant Offering
- Offering Size: Xilio Therapeutics announced the pricing of pre-funded warrants at $0.5349 each for 74,780,300 shares, with expected gross proceeds of approximately $40 million, indicating strong market interest in the company's offerings.
- Use of Proceeds: The net proceeds from this offering will be utilized to advance the development of product candidates and for working capital needs, highlighting the company's commitment to future R&D and market opportunities.
- Investor Participation: The financing was led by existing investor Coastlands Capital and included participation from institutional investors like Gilead Sciences, reflecting strong market confidence and support for Xilio's strategic direction.
- Underwriting Arrangement: Leerink Partners is acting as the sole bookrunner for the offering, ensuring professionalism and efficiency in the financing process, which also lays a solid foundation for future capital operations.
See More
